TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02942199

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MySafeRx
Description: The MySafeRx platform is a combination of several key components, including daily videoconferencing check-ins with motivational interviewing-based recovery coaching, text-messaging reminders, secure storage of buprenorphine medication within a secure electronic pill dispenser (i.e., MedicaSafe 3000), and a standardized protocol for supervising self-administration of medication via videoconferencing.
Study: NCT01448746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low molecular weight heparin
Description: 40mg 12 hours before surgery and 12 hours later surgery
Study: NCT04502329

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet
Description: Energy Restriction Intermittent Fasting Diet
Study: NCT01273831

Intervention type: DRUG
Group type: OTHER
Intervention: atracurium
Description: atracurium, Drop,0.5 mg/kg, one time, one day

Intervention type: DRUG
Group type: OTHER
Intervention: cisatracurium
Description: cisatracurium, drop,0.15mg/kg,one time, one day
Study: NCT02359669

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: StimuLearn Intervention
Description: * StimuLearn apps~* Cognitive questionnaires

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Without StimuLearn intervention
Description: Cognitive Questionnaires
Study: NCT03365765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Oxaliplatin Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin Intravenous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluorouracil
Description: 5-fluorouracil Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: 5-fluorouracil Intravenous
Study: NCT03087591

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: siRNA-transfected Peripheral Blood Mononuclear Cells (PBMC) APN401
Description: Given IV
Study: NCT02007486

Intervention type: OTHER
Intervention: Cardiopulmonary Exercise Testing
Description: Symptom-limited incremental exercise testing (10 watts/min) on an electronically braked cycle ergometer

Intervention type: OTHER
Intervention: Cardiopulmonary Exercise Testing
Description: Symptom-limited incremental exercise testing (10 watts/min) on an electronically braked cycle ergometer

Intervention type: OTHER
Intervention: Cardiopulmonary Exercise Testing
Description: Symptom-limited incremental exercise testing (10 watts/min) on an electronically braked cycle ergometer

Intervention type: OTHER
Intervention: Cardiopulmonary Exercise Testing
Description: Symptom-limited incremental exercise testing (10 watts/min) on an electronically braked cycle ergometer
Study: NCT01415505

Intervention type: DRUG
Group type: OTHER
Intervention: Nebivolol, Valsartan and Hydrochlorothiazide
Description: Nebivolol 5 mg (tablet), oral administration Nebivolol 10 mg (tablet), oral administration Nebivolol 20 mg (tablet), oral administration Valsartan 160 mg (tablet), oral administration Valsartan 320 mg (tablet), oral administration Hydrochlorothiazide 12.5 mg rescue medication (capsules), oral administration. Hydrochlorothiazide 25 mg rescue medication (capsules), oral administration
Study: NCT03431077

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Angiotensin II
Description: Angiotensin II is a peptide hormone naturally produced by the body that regulates blood pressure via vasoconstriction and sodium reabsorption. LJPC-501 (angiotensin II) is being developed for the treatment of hypotension in patients who do not respond to fluids and vasopressor therapy.
Study: NCT00991926

Intervention type: DRUG
Intervention: Orlistat
Description: orlistat (Xenical, Roche, UK)120 mg tid

Intervention type: OTHER
Intervention: normo-caloric diet
Description: Food intake and dietary history were assessed by a skilled dietitian who used a computer-assisted interview (Winfood 1.5, Medimatica srl, Martinsicuro, Italy)

Intervention type: OTHER
Intervention: normo-caloric diet
Description: Food intake and dietary history were assessed by a skilled dietitian who used a computer-assisted interview (Winfood 1.5, Medimatica srl, Martinsicuro, Italy)
Study: NCT01627392

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking abstinence
Description: 6 hour smoking abstinence
Study: NCT01006044

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous dendritic cells
Description: Patients will receive standard first-line therapy (surgery before radio-chemotherapy) along with the experimental treatment. The experimental treatment consists in subcutaneous vaccination with a suspension of autologous dendritic cells (cells from the same patient) produced by cell culture from monocytes from the same patient extracted by leukapheresis and pulsed with a lysate of the patient´s tumoral tissue. The first four vaccines will be administered on a monthly basis, concomitantly with the standard chemo and radiotherapy treatments, the next four vaccines, every other month and the four last vaccinations every three months.The results obtained will be compared with those of an historical control study, where patients received a standard treatment without the experimental vaccine.
Study: NCT02621606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [11C]MK-6884
Description: IV bolus dose of \~370 MBq \[11C\]MK-6884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [11C]MK-6884
Description: IV bolus dose of \~370 MBq \[11C\]MK-6884
Study: NCT01094873

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdCh3NSmut
Description: Genetic vaccines against Hepatitis C virus infection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdCh3NSmut
Description: Genetic vaccines against Hepatitis C virus infection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdCh3NSmut
Description: Genetic vaccines against Hepatitis C virus infection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdCh3NSmut
Description: Genetic vaccines against Hepatitis C virus infection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdCh3NSmut
Description: Genetic vaccines against Hepatitis C virus infection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdCh3NSmut
Description: Genetic vaccines against Hepatitis C virus infection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad6NSmut
Description: Genetic vaccine against Hepatitis C virus infection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad6NSmut
Description: Genetic vaccine against Hepatitis C virus infection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad6NSmut
Description: Genetic vaccine against Hepatitis C virus infection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad6NSmut
Description: Genetic vaccine against Hepatitis C virus infection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad6NSmut
Description: Genetic vaccine against Hepatitis C virus infection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad6NSmut
Description: Genetic vaccine against Hepatitis C virus infection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad6NSmut
Description: Genetic vaccine against Hepatitis C virus infection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad6NSmut
Description: Genetic vaccine against Hepatitis C virus infection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad6NSmut
Description: Genetic vaccine against Hepatitis C virus infection
Study: NCT02011802

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Algosteril TM

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sorbact TM
Study: NCT01796041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine Green
Study: NCT02584205

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Powerbreathe
Description: In this intervention we will use an equipment called powerbreathe classic light. It provides us to choose resistance levels with an adjustable load setting range: 1 to 9 and it's ideal for beginners. In this research we will use it on the intervention group to improve the strength of inspiratory muscle training and evaluate the results in the functional capacity of the subjects with obstructive sleep apnea.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Powerbreathe
Description: In this intervention we will use an equipment called powerbreathe classic light. It provides us to choose resistance levels with an adjustable load setting range: 1 to 9 and it's ideal for beginners. In this research we will use it on the intervention group to improve the strength of inspiratory muscle training and evaluate the results in the functional capacity of the subjects with obstructive sleep apnea.
Study: NCT02621606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [11C]MK-6884
Description: IV bolus dose of \~370 MBq \[11C\]MK-6884
Study: NCT02048384

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin alone (Arm A)
Description: metformin alone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin (Arm B)
Description: rapamycin + metformin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rapamycin (Arm B)
Description: rapamycin + metformin
Study: NCT02692248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib 560 mg daily for 14 days during induction cycles. Maintenance phase: Continuous cycles until disease progression or unacceptable toxicity (maximum of 2 years).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375 mg/m2 IV day 1 during 4 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m2 IV (30-minute infusion) on day 1 or 2, 4 cycles every 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin 100 mg/m2 (3-hour infusion) on day 1 or 2, after Gemcitabine infusion, 4 cycles every 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 20 mg orally or IV on day 1 and orally on days 2-3, 4 cycles every 14 days.
Study: NCT03112044

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir-velpatasvir (400 mg/100 mg)
Description: Patients will have standard monitoring with HCV RNA and liver panel assessment at 2 week intervals until HCV is undetectable and then at the end of treatment and 3 and 6 months following its completion. Post-operative transplant care and immunosuppression will be carried on as usual transplant practice at Toronto General Hospital.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ex Vivo Lung Perfusion (EVLP)
Description: Normothermic EVLP is a method of donor lung preservation, assessment, treatment, and repair of injured organs. This method allows donor lungs to be treated for at least 12h under protective physiological conditions.
Study: NCT01826968

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Alveolar Recruitment maneuver
Description: In this group and during recruitment maneuver the investigators used pressure control ventilation and increased inspiratory time to 50%. The investigators used alveolar recruitment maneuver by increasing inspiratory pressure to 20 cmH20 and progressively increasing Positive Expiratory Pressure (PEEP) up to 45 cmH2O maximal (Ppeak) inspiratory pressure. The recruitment maneuver lasted 2 minutes. After the maneuver PEEP was set to 8 cmH2O and was left until the end of the operation. After the end of the recruitment maneuver volume control ventilation was used until the end of the operation too.
Study: NCT03512067

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Patients given EMV Ventilation
Description: Baseline mechanical ventilation data with conventional pressure-limited assist/control ventilation mode will then be collected for a 4-hour period. The patients will then be transitioned to pressure-limited entrainment-based ventilation for a 4-hour period. Baseline ventilation monitoring will be carried out either immediately preceding or immediately following EMV in the same patient. The sequence of the control/baseline phase and the experimental phase of the study will be randomized.
Study: NCT02039505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab
Description: Vedolizumab intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab
Description: Vedolizumab intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab
Description: Vedolizumab intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab
Description: Vedolizumab intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab
Description: Vedolizumab intravenous infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vedolizumab placebo
Description: Vedolizumab placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab placebo
Description: Vedolizumab placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vedolizumab placebo
Description: Vedolizumab placebo
Study: NCT00761501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PN400
Description: Oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen (Proxen S)
Description: Oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen (Naprosyn E)
Description: Oral
Study: NCT04476017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAGE-718
Description: Oral tablets.
Study: NCT01366833

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Brachytherapy
Description: Patients in arm B will receive a single dose of brachytherapy (10Gy) via a 10 or 13 mm catheter within 10days of stent insertion. Patients on the study will not be given preferential treatment, and will not be prioritized over patients treated with brachytherapy not on the study.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stent insertion
Description: After placement of clips to mark the proximal and distal extent of the tumor, an endoscopically placed self-expanding metallic stent (WallFlex™ Partially Covered Esophageal Stent by Boston Scientific) will be inserted within 10 days of recruitment. This will be the only intervention in Arm A patients.
Study: NCT00004010

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bleomycin sulfate

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABVD regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dacarbazine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: procarbazine hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinblastine sulfate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT03636152

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MRI carotid
Description: To assess the carotid atherosclerotic plaques
Study: NCT02199834

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer support
Description: 15 patients who have good glycemic control and self-care will be trained as peer supporters to deliver peer support under supervision by a program manager. Peer supporters will call their peers at least 12 times a year to provide both informational and emotional support.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized feedback report
Description: Patients will receive a personalized feedback report displaying trends of metabolic control of A1c, BP, LDL-C, and body weight, with automated decision support based on their own attained values every 4 months through mails.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Personalized feedback report
Description: Patients will receive a personalized feedback report displaying trends of metabolic control of A1c, BP, LDL-C, and body weight, with automated decision support based on their own attained values every 4 months through mails.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized feedback report
Description: Patients will receive a personalized feedback report displaying trends of metabolic control of A1c, BP, LDL-C, and body weight, with automated decision support based on their own attained values every 4 months through mails.
Study: NCT03636152

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: MRI carotid
Description: To assess the carotid atherosclerotic plaques
Study: NCT01714414

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3TC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3TC
Study: NCT03636152

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: APWV
Description: Doppler measurement of the APWV

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: APWV
Description: Doppler measurement of the APWV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine
Description: Active Drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Matching Placebo for the control group.
Study: NCT01836692

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiotherapy treatment
Description: Intensity Modulated Radiotherapy treatment
Study: NCT02270346

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Inspiratory muscle training
Description: Treatment group received inspiratory muscle training using threshold loading device (POWERbreathe Classic, IMT Technologies Ltd. Birmingham, England) at 40% of maximal inspiratory pressure (MIP).~The MIP was measured at supervised session each week, and 40% of measured MIP value was the new training workload.~The treatment group trained for 30 min-per/day, 7 days/week, for 6 weeks. Six sessions at home and 1 session were performed at department.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham inspiratory muscle training
Description: Control group received sham inspiratory muscle training using threshold loading device (POWERbreathe Classic IMT Technologies Ltd. Birmingham, England) at fixed workload, 5% of MIP.~The control group trained for 30 min-per/day, 7 days/week, for 6 weeks. Six sessions at home and 1 session were performed at department.
Study: NCT01714414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3TC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3TC
Study: NCT01664845

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: metformin 500mg tid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: pegylated-IFN
Description: pegasys 180 mcg qw

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pegylated-IFN
Description: pegasys 180 mcg qw

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ribavirin
Description: ribavirin 800-1200 mg qd according to BW

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ribavirin
Description: ribavirin 800-1200 mg qd according to BW
Study: NCT00836823

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alfuzosin
Description: Alfuzosin 10mg once daily for 12 months
Study: NCT01998373

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: training leaflet and oral training
Description: The intervention consisted of training leaflet and oral training. All of the patients were new cases and were divided into 2 groups. All patients were treated with routine medication, no addition medication for two groups were done, the case group attended the workshops and were trained In addition to medical therapy, continuing education and training workshop. The result of the effect of workshop was also filling out a questionnaire before and after training. Finally, two groups with statistical analysis were compared.
Study: NCT03145116

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CT ASPHINA 509
Description: Intraocular lens
Study: NCT03826277

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Melanostop peel
Description: Melanostop peel treatments containing 20% azelaic acid, 10% resorcinol, 6% phytic acid, 3% tranexamic acid. (4 treatments, performed at 2-week intervals), in combination with home care products (twice daily):~* a facial tonic and cream containing brightening ingredients: vitamin C, niacinamide, alpha arbutin, kojic acid,~* sunscreen protection cream with SPF 50, protecting against UVA, UVB, HEV and IR
Study: NCT01714414

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EFV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EFV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EFV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EFV
Study: NCT03879018

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reach training with visual feedback
Description: Reach training will be accomplished using an Oculus Rift and Touch 3D headset. Active markers will be placed on the shoulder, elbow, wrist, and finger in order to capture limb movement in real time. During each training session, participants will first be familiarized with the task and then will reach from a home position to 4 virtual targets that are presented in the front of the participant and within the workspace where most natural arm movements are performed.Targets will be presented in a pseudorandom order and participants will reach a total of 400 times

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reach training with visual feedback
Description: Reach training will be accomplished using an Oculus Rift and Touch 3D headset. Active markers will be placed on the shoulder, elbow, wrist, and finger in order to capture limb movement in real time. During each training session, participants will first be familiarized with the task and then will reach from a home position to 4 virtual targets that are presented in the front of the participant and within the workspace where most natural arm movements are performed.Targets will be presented in a pseudorandom order and participants will reach a total of 400 times
Study: NCT01049906

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Placement of nerve block catheter
Description: Placement of nerve block catheter with nerve stimulator and ultrasound

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Placement of nerve block catheter
Description: Placement of nerve block catheter with ultrasound only